Achieving Organizational Excellence is Possible by Promoting Employee Health and Mindfulness

 

Employee health and well-being have become a critical focus for organizations in today’s rapidly evolving workplace. With the increasing prevalence of chronic stress and burnout, especially in healthcare, the stakes are higher than ever. Research shows that  80% of chronic diseases are preventable, emphasizing the need for effective workplace health strategies.

How can leaders create a work environment that prioritizes and promotes employee health and well-being?

On this episode of “Holistic Leadership: The Future of Work & Education in Healthcare,” host Geoffrey M. Roche welcomes Dr. Richard Safeer, Chief Medical Director of Employee Health and Well-being at Johns Hopkins Medicine. They delve into Dr. Safeer’s work and insights from his book, “A Cure for the Common Company.”

Main Points of Conversation:

  • The importance of integrating well-being into organizational strategic plans and measuring its impact.
  • The role of leadership and culture in fostering a supportive environment for employee health.
  • Practical steps for implementing a culture of health framework in the workplace.

Dr. Richard Safeer is a recognized leader in the field of employee health and well-being. He currently serves as the Chief Medical Director of Employee Health and Well-being at Johns Hopkins Medicine and is the author of “A Cure for the Common Company.” Dr. Safeer is board-certified in three medical specialties, a fellow in three medical colleges, and has been acknowledged by a former Maryland governor for his contributions to public health. His work has been featured by the CDC, and he has been quoted in major publications like the Wall Street Journal, the Washington Post, and Fortune Magazine.

Recent Episodes

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…